| Drug ID: | Drug101 |
|---|
| Drug Name: | Semapimod |
|---|
| CID: | 5745214 |
|---|
| DrugBank ID: | DB12094 |
|---|
| Modality: | Small Molecule |
|---|
| Groups: | NULL |
|---|
| US Approved: | NULL |
|---|
| Other Approved: | NULL |
|---|
| Identifier: |
NULL
|
|---|
| Molecular Formula: | C34H52N18O2 |
|---|
| Molecular Weight: | 744.9 g/mol |
|---|
| Isomeric SMILES: | C/C(=N\\N=C(N)N)/C1=CC(=CC(=C1)NC(=O)CCCCCCCCC(=O)NC2=CC(=CC(=C2)/C(=N/N=C(N)N)/C)/C(=N/N=C(N)N)/C)/C(=N/N=C(N)N)/C |
|---|
| Synonyms: | Semapimod; 352513-83-8; Semapimod [INN]; CNI-1493; UNII-9SGW2H1K8P; CPSI-2364 FREE BASE; 9SGW2H1K8P; AXD455; Semapimod HCl; CPSI 2364 |
|---|
| Phase 0: | 0 |
|---|
| Phase 1: | 0 |
|---|
| Phase 2: | 0 |
|---|
| Phase 3: | 0 |
|---|
| Phase 4: | 0 |
|---|
| Description: | NULL |
|---|
-
-
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
| dt860 |
5745214 |
Semapimod |
2904 |
GRIN2B
|
Homo sapiens (human) |
|
Inhibitor |
| dt861 |
5745214 |
Semapimod |
1432 |
MAPK14
|
Homo sapiens (human) |
9205949 |
MAP kinase p38 alpha inhibitor |
| dt862 |
5745214 |
Semapimod |
5894 |
RAF1
|
Homo sapiens (human) |
37713619 |
Modulator |
| dt863 |
5745214 |
Semapimod |
5894 |
RAF1
|
Homo sapiens (human) |
|
Modulator |
| dt864 |
5745214 |
Semapimod |
1432 |
MAPK14
|
Homo sapiens (human) |
|
Inhibitor |
| dt865 |
5745214 |
Semapimod |
5600 |
MAPK11
|
Homo sapiens (human) |
|
None |
| dt866 |
5745214 |
Semapimod |
5894 |
RAF1
|
Homo sapiens (human) |
|
None |
| dt867 |
5745214 |
Semapimod |
1432 |
MAPK14
|
Homo sapiens (human) |
|
None |
| dt868 |
5745214 |
Semapimod |
6300 |
MAPK12
|
Homo sapiens (human) |
|
None |
| dt869 |
5745214 |
Semapimod |
5603 |
MAPK13
|
Homo sapiens (human) |
|
None |
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
| No data available |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
| No data available |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
| No data available |
PMID: 20551461
Year: 2010
Relationship Type:
Mechanism
Score: 6.1
Comment in
Nat Rev Immunol. 2011 Jun;11(6):371.
Innate immune cells must be able to distinguish between direct binding to
microbes and detectio…
